There are emerging reports supporting the fact that proton-pump inhibitors competitively inhibit the metabolism of clopidogrel to its active metabolite and diminish its clinical efficacy, especially in patients on long-term dual antiplatelet therapy. In this article, we examine the current evidence and provide interpretation of the results along with practical recommendations for healthcare providers.
- cardiovascular outcome
- proton-pump inhibitor
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine